We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ultrasensitive Graphene Biosensors Detect Cancer Risk Biomarker

By Doris Mendieta, Contributing News Editor
Posted on 05 Oct 2014
An ultrasensitive biosensor utilizing the exceptional electronic and thermal properties of graphene has been used to detect molecules that indicate an increased risk of developing cancer.

The biosensor has been shown to be more than five times more sensitive than bioassay tests currently in use, and was able to provide results in a matter of minutes, opening up the possibility of a rapid, point-of-care diagnostic tool for patients.

Bioengineers the University of Swansea (UK) developed a viable biosensor by putting graphene onto a silicon carbide substrate under extremely high temperatures and low pressure to form the basis of the biosensor. More...
They patterned graphene devices, using semiconductor processing techniques, before attaching a number of bioreceptor molecules to the graphene devices. These receptors were able to bind to, or target, a specific molecule present in blood, saliva or urine.

The molecule, 8-hydroxydeoxyguanosine (8-OHdG), is produced when DNA is damaged and, in elevated levels, has been linked to an increased risk of developing several cancers. The team used X-ray photoelectron spectroscopy (VG Scienta; Pleasanton, CA, USA) and Raman spectroscopy (Renishaw, Illinois, IL, USA) to confirm that the bioreceptor molecules had attached to the graphene biosensor once fabricated, and then exposed the biosensor to a range of concentrations of 8-OHdG. When 8-OHdG attached to the bioreceptor molecules on the sensor, there was a notable difference in the graphene channel resistance, which the scientists were able to record.

The graphene sensor was capable of detecting 8-OHdG concentrations as low as 0.1 ng/mL which is almost five times more sensitive compared with enzyme-linked immunosorbent assays (ELISAs). The graphene biosensor was also considerably faster at detecting the target molecules, completing the analysis in a matter of minutes. The potential of the biosensor to diagnose and monitor a whole range of diseases as it is quite simple to substitute the specific receptor molecules on the graphene surface.

Owen Guy, PhD, an associate professor of engineering and coauthor of the study, said, “Graphene has superb electronic transport properties and has an intrinsically high surface-to-volume ratio, which make it an ideal material for fabricating biosensors. Now that we've created the first proof-of-concept biosensor using epitaxial graphene, we will look to investigate a range of different biomarkers associated with different diseases and conditions, as well as detecting a number of different biomarkers on the same chip.” The study was published on September 19, 2014, in the journal 2D Materials.

Related Links:

University of Swansea
VG Scienta  
Renishaw



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.